TY - JOUR
T1 - The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats
AU - Agus, D.
AU - Mann, R.
AU - Clayman, M.
AU - Kelly, C.
AU - Michaud, L.
AU - Cohn, D.
AU - Neilson, E. G.
N1 - Funding Information:
Acknowledgments The authors would like to thank Drs. Zalman Agus and Stanley manuscript, and Dale Clayborne for secretarial assistance. The Cyclophosphamide used in this study was a gift from Dr. Keith Wheeler. This work was supported in part by National Institutes of Health Grants AM-07006, AM-30280, AM-20553, and AM-07357. E.G.N. is the recipient of an Established Investigator Award (85-108) from the American Heart Association and its Pennsylvania affiliates. M.D.C, is the recipient of a Physician Scientist Award (AM-01303) from the National Institutes of Health.
PY - 1986
Y1 - 1986
N2 - We examined the effects of daily cyclophosphamide administration on the development and extent of tubulointerstitial nephritis produced in rats injected with tubular basement membranes in adjuvant. 15 mg/kg/day of cyclophosphamide completely blocked the development of interstitial lesions, while 2 mg/kg/day enhanced the degree of interstitial injury. When cyclophosphamide in the higher dose was started early in disease, 12 days after immunization, protection from progression was also observed as well as significant reductive improvement. If cyclophosphamide was administered late in disease, 21 days after immunization, no further progression was demonstrable, but substantial injury remained. In the latter two experiments, the beneficial effects of cyclophosphamide could not be explained by a reduction in anti-tubular basement membrane antibodies bound to the kidney. In groups of immunized rats that were tested, however, cyclophosphamide was able to non-specifically impair the delayed-type hypersensitivity response to tubular antigen and PPD. We conclude, therefore, that cyclophosphamide, in high but not low dosage, if given before damage is extensive and prolonged, may successfully inhibit the cellular immune response producing primary interstitial nephritis.
AB - We examined the effects of daily cyclophosphamide administration on the development and extent of tubulointerstitial nephritis produced in rats injected with tubular basement membranes in adjuvant. 15 mg/kg/day of cyclophosphamide completely blocked the development of interstitial lesions, while 2 mg/kg/day enhanced the degree of interstitial injury. When cyclophosphamide in the higher dose was started early in disease, 12 days after immunization, protection from progression was also observed as well as significant reductive improvement. If cyclophosphamide was administered late in disease, 21 days after immunization, no further progression was demonstrable, but substantial injury remained. In the latter two experiments, the beneficial effects of cyclophosphamide could not be explained by a reduction in anti-tubular basement membrane antibodies bound to the kidney. In groups of immunized rats that were tested, however, cyclophosphamide was able to non-specifically impair the delayed-type hypersensitivity response to tubular antigen and PPD. We conclude, therefore, that cyclophosphamide, in high but not low dosage, if given before damage is extensive and prolonged, may successfully inhibit the cellular immune response producing primary interstitial nephritis.
UR - http://www.scopus.com/inward/record.url?scp=0022648807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022648807&partnerID=8YFLogxK
U2 - 10.1038/ki.1986.46
DO - 10.1038/ki.1986.46
M3 - Article
C2 - 3702218
AN - SCOPUS:0022648807
SN - 0085-2538
VL - 29
SP - 635
EP - 640
JO - Kidney International
JF - Kidney International
IS - 3
ER -